Market Place
Sourcing Support
Biomind Labs Announces Positive Results of Phase 2 Trial of BMND08
29 Feb 2024 //
BUSINESSWIRE
Biomind Labs Provides Corporate Update
27 Sep 2023 //
BUSINESSWIRE
Biomind Labs Completes the Development of 5-MeO-DMT Synthesis Scheme
14 Sep 2023 //
BUSINESSWIRE
Biomind Labs Reaches High Purity & Yield of DMT Through an Optimized Extraction
31 Mar 2023 //
BUSINESSWIRE
Biomind Announces the Completion of the First Sublingual Psychedelic Formulation
28 Dec 2022 //
BUSINESSWIRE
Biomind Labs Announces FDA New Drug Clearance for New Chemical Entity Triptax
14 Nov 2022 //
BUSINESSWIRE
Biomind reports positive data from Phase II depression trial
08 Nov 2022 //
CLINICALTRIALSARENA
Biomind Announces Positive Results From PII Trial on Its BMND01 Candidate
04 Nov 2022 //
BUSINESSWIRE
Biomind Announces Pre-IND Meeting Request Granted by FDA for Triptax
11 Oct 2022 //
BUSINESSWIRE
Biomind & QU Receive License to Commence the Production of Drug Delivery System
27 Sep 2022 //
BUSINESSWIRE
Biomind Labs Announces Completion of Dosing in PII Trial of BMND01
21 Sep 2022 //
BUSINESSWIRE
Biomind Labs Appoints Former FDA Director Dr. Thomas Laughren as Medical Advisor
27 Jul 2022 //
BUSINESSWIRE
Biomind Labs Bags Approval for Third PII Trial for Its 5-MeO-DMT Based BMND08
26 May 2022 //
BUSINESSWIRE
Biomind Labs to Argument on Psychedelic Medicines at National Gallery in London
09 May 2022 //
BUSINESSWIRE
Biomind Labs Begins Dosing in PI/IIa Trial of BMND01
26 Apr 2022 //
BUSINESSWIRE
Biomind Labs to Present at Benzinga Psychedelics Capital Conference
30 Mar 2022 //
BUSINESSWIRE
Biomind Labs to Commence Commercial Clinical Trial of BMND06
24 Mar 2022 //
BUSINESSWIRE
Biomind Labs Opens a New Psychedelic Research Facility
17 Mar 2022 //
BUSINESSWIRE
Biomind Labs Opens a New Psychedelic Research Facility
16 Mar 2022 //
BUSINESSWIRE
Biomind Bags Approval for 2nd Phase II Trial for Treatment-resistant Depression
09 Mar 2022 //
BUSINESSWIRE
Biomind Labs Announces Positive Results on in vivo Studies for BMND07
03 Mar 2022 //
BUSINESSWIRE
Biomind Labs Announces DTC Eligibility in the United States
24 Feb 2022 //
BUSINESSWIRE
Biomind Labs Announces Upgrade to the OTCQB Venture Market in the U.S.
17 Feb 2022 //
BUSINESSWIRE
Biomind to Design a Pharmaceutical Form for Psychedelic Drug Delivery
24 Nov 2021 //
BUSINESSWIRE
Biomind Labs Completes Development of Thermosensitive Nasal Gel
18 Nov 2021 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.